Elkfork Partners’s Acceleron Pharma XLRN Stock Holding History

Elkfork Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$29K	Sell	726 -110	-13%	-$4.77K	﹤0.01%	1012
2019 Q2	$34K	Sell	836 -6,226	-88%	-$258K	﹤0.01%	1010
2019 Q1	$329K	Sell	7,062 -44	-0.6%	-$1.93K	0.01%	676
2018 Q4	$309K	Sell	7,106 -5,258	-43%	-$263K	0.01%	663
2018 Q3	$708K	Sell	12,364 -242	-2%	-$11.9K	0.02%	478
2018 Q2	$612K	Buy	12,606 +1,386	+12%	+$50.5K	0.02%	474
2018 Q1	$439K	Buy	+11,220	New	+$477K	0.01%	569

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Elkfork Partners's XLRN Position: Q3 2019 in Review

Elkfork Partners reduced its Acceleron Pharma (XLRN) stake by 13% in Q3 2019, selling an estimated $4.77K and leaving 726 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Elkfork Partners first reported a position in XLRN in Q1 2018 and has held it in 7 quarters since. The position peaked at $708K in Q3 2018. 172 funds tracked by Wall St. Rank hold XLRN as of Q3 2019.

Elkfork Partners held 726 shares of Acceleron Pharma worth $29K as of Q3 2019.
Elkfork Partners sold 110 Acceleron Pharma shares in Q3 2019, an estimated $4.77K.
Acceleron Pharma made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1012 holding.
Elkfork Partners first reported a position in Acceleron Pharma in Q1 2018 and has held it in 7 quarters since.
Elkfork Partners's Acceleron Pharma position peaked at $708K in Q3 2018.
172 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.